Compare ADMA Biologics Inc (ADMA) vs Bath & Body Works Inc (BBWI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Bath & Body Works Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Bath & Body Works Inc trades at $19.46 (market cap $4.16B). The key difference: Bath & Body Works Inc is the larger of the two by market cap, and Bath & Body Works Inc pays a 3.88% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BBWI | |
|---|---|---|
Market Cap | $2.13B | $4.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $33.65 |
52-Week Low | $7.60 | $14.85 |
Enterprise Value | $2.20B | $8.05B |
Dividend Yield | — | 3.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
BBWI trades at $20.62, down 6.1% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The stock is valued attractively with a P/E of 6.23 and P/S of 0.62, while recent earnings beat expectations in Q1 2026. Revenue has declined over five years, but the company maintains strong cash flow and a new partnership with Ulta Beauty aims to expand reach.
The outlook is mixed: deep valuation discounts and strategic initiatives like the Ulta partnership offer upside, but persistent revenue declines and high debt pose risks. Analyst consensus is a $22.50 price target with no sell ratings, indicating cautious optimism for a turnaround if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →
